Due to garage renovations at our Alexandria office, please arrive 15 minutes early to allow sufficient time for parking. We thank you for your patience.

Comfort Without Compromise

The Mammogram Exam Just Got More Comfortable!

When it comes to your mammogram, accuracy and peace of mind are key. At AAR, our commitment to the highest quality patient care is our first priority.

AAR is now proud to offer the SmartCurve™ breast stabilization system, which is clinically proven to deliver a more comfortable mammogram without compromising image quality, workflow or dose.

This latest innovation is part of AAR’s ongoing commitment to superior breast cancer detection and has the potential to increase patient compliance for the countless women who have reported avoiding regular mammograms due in large part to the fear of discomfort associated with breast compression.

The SmartCurve system features a proprietary curved surface that mirrors the shape of a woman’s breast to reduce pinching and allow better distribution of force over the entire breast. In a recent clinical study comparing the SmartCurve breast stabilization system to traditional flat paddle compression, the SmartCurve system improved comfort in 93 percent of women who reported moderate to severe discomfort with standard compression.1 In addition, 95 percent of those surveyed would recommend facilities that use the system.1

The SmartCurve system is available at AAR and detects more invasive cancers, reduce false positives, and is FDA approved as superior to conventional 2D mammography for all women, including those with dense breasts

Breast Cancer Statistics:

  • 1 in 8 women will develop breast cancer over the course of her lifetime
  • 85% of breast cancers occur in women who have no family history of breast cancer
  • Risk of breast cancer increases if a woman has a first degree relative who has been diagnosed

What is a 3D mammogram?

A 3-dimensional (3D) mammogram is an FDA approved technology that takes multiple low dose projection images of the breast tissue to create a 3-dimensional image of the entire breast. 3D mammography takes only a few more seconds than 2D imaging.

What are the benefits of 3D mammography?

All patients benefit from 3D mammography, it is especially valuable for women receiving a baseline screening or those who have dense breasts. 3D mammography helps reduce the need for additional images or unnecessary procedures.

3D mammography is also helpful for women with dense breast tissue. Dense breast tissue can hide small tumors with traditional 2D mammography. Our 3D mammography unit obtains images of the breast from multiple angles allowing the radiologist to view the breast tissue one slice at a time. This advanced technology helps detect cancers earlier than conventional 2D mammography.

Make Your Appointment

To make your screening appointment, please call our office at 703-824-3260. Please note that some screening exams require a referral from your physician.

To learn more about AAR and all our services, click here!


[1] Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00119 Rev 003 (2017).

[1] Results from Friedewald, SM, et al. “Breast cancer screening using tomosynthesis in combination with digital mammography.” JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3DÔ mammograms acquired with the Hologic 3D MammographyÔ system versus women receiving 2D FFDM mammograms only.

[1] Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.

[1] U.S. Food & Drug Administration Premarket Approval (PMA).  FDA.gov https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080003 accessed June 5, 2017.

2018-08-31T16:52:09-04:00August 31st, 2018|Uncategorized|